



Applicant(s):

Feige, et al.

Serial No.:

09/428,082

Filed:

October 22, 1999

For:

Modified Peptides as Therapeutic Agents

Docket No.:

A-527

JUN 0 7 2002

Group Art Unit No.:

Examiner:

S. Huff

JUN 1 3 2002

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

The Applicants provision of these references under this and any other Information Disclosure Statement should not be deemed an admission that all such references are relevant to patentability nor are necessarily prior art in accordance with 35 U.S.C. §102. Each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519. An original and one copy are enclosed.

Respectfully submitted,

Timothy J. Sau

Attorney for Applicants

Registration No.:

33,111

Phone: (805) 447-2688

Date: June 7,2002

Please send all future correspondence to: **US Patent Operations/TJG** Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

Express Mail mail tabeling number: EL360693917US

Date of Deposit:

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addre ed to the Assistant Commissioner for Patents, Washington, D.C. 2023